Cognoptix has developed a diagnostic system to aid in the early detection of Alzheimer’s Disease (AD). The SAPPHIRE II eye test is designed to identify Alzheimer’s Disease (AD) patients via a beta-amyloid (A-beta) signature in their eyes.  Significantly faster and an order of magnitude less expensive than PET brain imaging, the test and diagnosis are designed to be quickly completed in any physician’s office, including general practitioners.

In a Phase II clinical trial,  SAPPHIRE II achieved a sensitivity of 85% and a specificity of 95% in differentiating 20 patients who were clinically diagnosed with probable AD from a group of 20 age-matched healthy volunteers. In addition, the SAPPHIRE II test showed excellent correlation to PET (positron emission tomography) amyloid brain imaging.  The results of this multicenter clinical trial have been published in the Journal of Alzheimer’s Disease and Other Dementias (Detection of Amyloid β Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer’s Disease. AM J ALZHEIMERS DIS OTHER DEMEN1533317513520214; February 13, 2014)

Learn more:

Christine de los Reyes
Business Development